SCHEMBL2190740

SCHEMBL2190740

O[C@@H]1CN(Cc2ccccc2)CC[C@H]1Nc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FUCA1 P04066 2/20 0.58
UBE2M P61081 1/20 0.55
DCUN1D1 Q96GG9 1/20 0.55
ALDH1A1 P00352 2/20 0.52
FAAH O00519 1/20 0.52
SLC18A3 Q16572 1/20 0.52
KMT2A Q03164 2/20 0.51
DRD2 P14416 1/20 0.51
DRD4 P21917 1/20 0.51
DRD3 P35462 1/20 0.51
MAPK1 P28482 1/20 0.51
BCHE P06276 4/20 0.50
ACHE P22303 2/20 0.50
BACE1 P56817 1/20 0.50
KDM4E B2RXH2 1/20 0.50
MAPT P10636 1/20 0.50
GBA1 P04062 1/20 0.50
MAOB P27338 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12507213 1.00 FUCA1 (0.58) FUCA1UBE2MDCUN1D1ALDH1A1FAAH
SCHEMBL2190734 1.00 FUCA1 (0.58) FUCA1UBE2MDCUN1D1ALDH1A1FAAH
SCHEMBL2190729 1.00 FUCA1 (0.58) FUCA1UBE2MDCUN1D1ALDH1A1FAAH
SCHEMBL2190830 0.91 SMN1; SMN2 (0.57) FUCA1UBE2MDCUN1D1ALDH1A1FAAH
SCHEMBL2190834 0.91 SMN1; SMN2 (0.57) FUCA1UBE2MDCUN1D1ALDH1A1FAAH
SCHEMBL2190839 0.91 SMN1; SMN2 (0.57) FUCA1UBE2MDCUN1D1ALDH1A1FAAH
SCHEMBL2191725 0.90 ALDH1A1 (0.57) FUCA1UBE2MDCUN1D1ALDH1A1FAAH
SCHEMBL2191719 0.90 ALDH1A1 (0.57) FUCA1UBE2MDCUN1D1ALDH1A1FAAH
SCHEMBL2191712 0.90 ALDH1A1 (0.57) FUCA1UBE2MDCUN1D1ALDH1A1FAAH
SCHEMBL2790128 0.90 FUCA1 (0.63) FUCA1UBE2MDCUN1D1ALDH1A1FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2351738-A1 PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO)PIPERIDIN-3-OL Sumitomo Chemical Company, Limited (JP) 2011-08-03 EP disclosed
US-20110172431-A1 PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO) PIPERIDIN-3-OL SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-07-14 US disclosed
US-20110172431-A1 PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO) PIPERIDIN-3-OL SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172431-A1 PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO) PIPERIDIN-3-OL TEAD4, TEAD3, TEAD2 FUCA1 2251/4885UBE2M 4657/4885DCUN1D1 3426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.